Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HuRicell-Hepa
- Development stage
- Preclinical
- Lead developer
- Hurimbiocell
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
HuRicell-Hepa is an investigational allogeneic cell therapy developed by Hurimbiocell for the treatment of liver diseases, including hepatitis, liver cirrhosis, fatty liver, and liver cancer. The therapy utilizes cord-derived mesenchymal stem cells (MSCs) and is designed for potential mass production. Hurimbiocell completed nonclinical and GLP studies for HuRicell-Hepa under a support project funded by the Ministry of Knowledge Economy (MOKE) of South Korea, which provided 2.5 billion KRW in research funds.
- Brand names
- HuRicell-Hepa™
- Other names
- HuriCell-Hepa
Beyond the preview
Go deeper on HuRicell-Hepa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HuRicell-Hepa.